monoubiquitylate PCNA and that this modification is requisite for chain extension by Ubc13-Mms2-Rad5. This finding is expected from earlier in vivo studies. Whereas Rad6-Rad18 has exquisite specificity for K164, Parker and Ulrich demonstrate that N-and C-terminal fused ubiquitins can also stimulate PCNA polyubiquitylation by Ubc13-Mms2-Rad5. Altogether, they provide compelling evidence for the sequential and independent activity of the two E2-E3 pairs. Ulrich is an expert in the PCNA field and the multiple models presented in Figure 1 demonstrate depth of thought towards this pathway and expose clearly the multiple mechanisms tested. Some technical aspects should be addressed prior to publication.
1. In Figure 2 (and others) very little PCNA is actually modified. As noted in the text, when PCNA is fused with an N-terminal ubiquitin ( Figure 4B ) a substantial amount is modified under appropriate conditions. Is PCNA fused to an N-terminal His tag? The Methods section references a 2008 paper that would suggest that it is. It is possible that this difference is because the N-terminal his tag somehow interferes with PCNA assembly or recognition by Rad6-Rad18. Alternatively, could a DUB be co-purified with Rad6-Rad18? It would be worthwhile to repeat one assay (not necessarily every experiment using recombinant PCNA) with an untagged version in which the tag is cleaved off and/or to check for the presence of a DUB. Not addressing this point further could lead to incorrect interpretations. Figure 5 were complemented with anti-ubiquitin blots. In Figure 5A , when K63 linked tetraubiquitin was used in the thioester assay under non-reducing conditions PCNA is barely visible in the gel, even in its unmodified form. It doesn't seem appropriate to interpret this result as K63 linked tetraubiquitin being less competent for thioester formation by Rad6, as presented in the text.
It would be better if
Referee #2 (Remarks to the Author):
Mechanistic analysis of PCNA polyubiquitylation by the ubiquitin protein ligases Rad18 and Rad5 Joanne L. Parker and Helle D. Ulrich* In this manuscript Parker et al. use an in vitro system to determine the mechanism of polyubiquitin chain formation of the replication clamp PCNA. This is known to occur with two E2-E3 pairs.
The mechanism of polyubiquitin chain formation remains complex and probably differs dependent upon the substrate and the responsible E2-E3 pairs. There are in vitro and in vivo examples where a single E2-E3 pair is capable of both initiating and elongating the chain, there are examples of a single E3 utilising two E2s to initially monoubiquitinate and then elongate, and there are examples of separate E2-E3 pairs responsible for initiation and subsequent elongation of the chain. In addition whether the polyubiquitin chain is built on the substrate, or transferred en bloc remains unclear.
In the present manuscript the authors consider the modification of the PCNA replication clamp following DNA damage tolerance -a system that requires separate E2-E3 pairs. They use this model system to analyse the possible mechanism of chain formation in vitro -using purified components.
In general this was a well-presented clearly written paper. Their conclusion that their results support model A, where Rad6-Rad18 and Ubc13-Mms2-Rad5 act sequentially and mediate PCNA polyubiquitylation by stepwise addition of ubiquitin monomers seems to be reasonably justified by their experiments.
I had a few points which might be helpful to address.
Figure 5 is quite complex and not trivial to follow. It would help the reader if each blot was more clearly labeled -in particular as to what was being blotted! -this is in the text but it does take some working out.
On page 10 they say that 'all derivatives were efficiently attached to the substrate (5D)'. However, the K63R mutant is not attached beyond a single ubiquitin attached to the monoubiquitinated substrate -which is what one might have predicted -but this is not what is described in the text?
They are certainly not exhaustive in their referencing on different systems using more than one E2 -and they might consider mentioning these in their discussion. For example Christensen et al (Nat Cell Bio 2007) looked at how different E2s affect synthesis of mono-or specific polyubiquitin chain linkages, and Duncan et al (EMBO J 2006) showed that different E2s and E3s are responsible for initiation and chain elongation of their MHC I substrate.
Referee #3 (Remarks to the Author):
In their manuscript, "Mechanistic analysis of PCNA polyubiquitylation by the ubiquitin protein ligases Rad18 and Rad5," Parker and Ulrich explore the mechanism underlying poly-ubiquitylation of the protein PCNA. Mono-ubiquitylation of PCNA at conserved lysine 164 activates the translesion synthesis response to DNA damage while K63 linked poly-ubiquitylation activates a bypass mechanism leading to post-replication repair. Strong genetic evidence and biochemical analysis have previously revealed that mono-ubiquitylation of PCNA is driven by the ubiquitin E2/E3 pair Rad6/Rad18. In vivo, both Rad6/Rad18 and Ubc13-Mms2/Rad5 are necessary for polyubiquitylation of PCNA. However, it is unclear whether poly-ubiquitylation is downstream or parallel to mono-ubiquitylation and, as the authors propose in Figure 1 , several mechanisms are consistent with data in the published literature.
The proposed mechanisms address several major themes in the literature on how ubiquitin chains are built. First, where is the chain assembled? As the authors note, for RING ligase systems a polyubiquitin chain can be built on substrates, on the active site of the E2, or free chains may be activated by the E1. Second, do multiple E2/E3's cooperate to build and attach the chain? Third, is lysine selection specific?
In this manuscript, the authors provide the first clear evidence that, in the absence of DNA/RFC and Rad6/Rad18, Rad5 and Ubc13/Mms2 are sufficient for poly-ubiquitylation of a mono-ubiquitylated PCNA. They go on to show that N-terminal and C-terminal ubiquitin PCNA fusions also serve as substrates of Rad5 and Ubc13/Mms2 providing evidence that the position of the primer ubiquitin on PCNA may not be critical. The authors also provide evidence that both E2/E3 pairs are capable of passing pre-formed chains, yet these chains are not built on the active site of either E2 and there is a preference for mono-ubiquitin. One main drawback of the paper is the lack of a quantitative assay. However, many of the general conclusions that the authors make are clear even without this. The manuscript and its conclusions are fit for publication in EMBO, as long as the specific issues below are addressed.
Since the active site chain building properties of hUbc7 are stimulated by the presence of its of E3 gp78, the experiments shown in figure 5a and 5c need to be repeated in the presence of the E2's respective E3. The data in Figure 5e is unreadable. The exposure should be dark enough that the wild type lane matches data presented in previous figures. The data in Figure 5d and 5e needs to be repeated with time courses as seen in Figure 4d and Figure 2b to substantiate the claims that there is a differential in chain length usage. Response to the reviewers' comments Referee #1 (Remarks to the Author): Figure 4B) All experiments with PCNA presented in this manuscript were performed with untagged PCNA, except for the linear His Ub-PCNA and His PCNA-Ub fusions. The low degree of modification is therefore not attributable to any tag. Likewise, we consider it unlikely that a DUB is present in our Rad6-Rad18 preparation, because prolonged incubation of partially monoubiquitylated PCNA with additional Rad6-Rad18 in the absence of DNA/RFC does not lead to a reduction in the level of modification (see Fig. 3A) , and the preassembled chains used for the experiments shown in Fig. 5 are not disassembled by incubation with Rad6-Rad18 ( Fig. 5B and S1A) . Instead, we believe that the sometimes inefficient modification of PCNA by Rad6-Rad18 reflects the unpredictable behaviour of Rad18 that has already been described by the lab of Peter Burgers (Garg and Burgers, PNAS 2005), including a limited lifetime in conjugation assays and a sensitivity to the reaction scale. We have now indicated the use of untagged PCNA in the Materials and Methods section. Figure 5 were complemented with anti-ubiquitin blots. In Figure  5A ,
In Figure 2 (and others) very little PCNA is actually modified. As noted in the text, when PCNA is fused with an N-terminal ubiquitin (
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when K63 linked tetraubiquitin was used in the thioester assay under non-reducing conditions PCNA is barely visible in the gel, even in its unmodified form. It doesn't seem appropriate to interpret this result as K63 linked tetraubiquitin being less competent for thioester formation by Rad6, as presented in the text.
As commented on by referee #2, Figure 5 is quite complex and was not labelled very clearly. We have now revised this Figure and added more labels to the blots, which should make it more readable and hopefully resolve the confusion. This will make clear that Figure 5A represents a thioester assay with Rad6, with no PCNA present in the reaction. Hence, the blot was developed with an anti-Rad6 antibody. The virtual absence of "unmodified" Rad6 in some of the lanes indicates near complete conversion to the thioester. Anti-ubiquitin blots would be difficult to interpret due to a differential recognition of ubiquitin polymers of different lengths by the anti-ubiquitin antibody. We therefore do not think that they would add meaningful information.
Figure 5 is quite complex and not trivial to follow. It would help the reader if each blot was more clearly labeled -in particular as to what was being blotted! -this is in the text but it does take some working out.
We agree that Figure 5 was poorly labelled and therefore difficult to understand. We have addressed this by clearly labelling the respective panels as "Thioester assay"or "Conjugation assay", respectively, and indicating the relevant E2 as well as the antibodies used for the blots.
On page 10 they say that 'all derivatives were efficiently attached to the substrate (5D)'.
However, the K63R mutant is not attached beyond a single ubiquitin attached to the monoubiquitinated substrate -which is what one might have predicted -but this is not what is described in the text?
We have added a sentence to that effect on pg. 11.
They are certainly not exhaustive in their referencing on different systems using more than one E2 -and they might consider mentioning these in their discussion. For example Christensen et al (Nat Cell Bio 2007) Figure  5d and 5e needs to be repeated with time courses as seen in Figure 4d and Figure 2b to substantiate the claims that there is a differential in chain length usage.
We have repeated the thioester assays with Rad6 and Ubc13 (Figures 5A and C) in the presence of their respective E3s. These data, shown as supplementary Figure S1 , indicate that the E3s do not significantly affect (either positively or negatively) thioester formation.
We have also repeated the experiment shown in Figure 5E and now provide a better image. Conjugation in the absence of RFC/DNA is still rather poor, but the modification pattern is clearly visible in their presence.
Finally, we have performed time course experiments for the modification reactions shown in Figure 5D (now shown as supplementary Figure S2 ). The data indicate that there is some preference for monomers or short chains, although the difference is not as pronounced as in the case of Rad6-Rad18. Due to the difficulties in obtaining large amounts of purified monoubiquitylated PCNA and the similarities of the patterns shown in Figures 5D and E we have performed time course experiments only with the His Ub-PCNA fusions and not with K164-modified PCNA.
